Intercept Pharmaceuticals, Servier deal

The companies partnered to discover and develop treatments for Type II diabetes and other metabolic diseases from Intercept's G protein-coupled bile acid receptor 1 ( GPBAR1; TGR5) agonist program. The partners will use Intercept's drug discovery technology, which is based on bile acid analog chemistry. Servier will have rights to the products outside of the U.S. and Japan, where Intercept retains rights. ...